New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
07:32 EDTBIIB, ELNBiogen, Elan announce results from several TYSABRI studies
Biogen Idec (BIIB) and Elan Corporation (ELN) announced results from several studies of TYSABRI that demonstrate its efficacy compared to other multiple sclerosis treatments, provide additional data supporting anti-JC virus antibody status stability, and suggest better outcomes when progressive multifocal leukoencephalopathy is detected early. These data will be presented at the 65th Annual Meeting of the American Academy of Neurology in San Diego. “These new data reinforce our belief in the substantial efficacy TYSABRI has demonstrated at both the early and advanced stages of relapsing forms of MS,” said Alfred Sandrock, M.D., Ph.D., senior vice president, Development Sciences and chief medical officer, Biogen Idec. “We are also encouraged by the consistency in anti-JCV antibody status demonstrated over 18 months, as well as results from our pursuit of additional paths to help mitigate the impact of PML. These combined efforts may allow a more individualized approach when selecting TYSABRI treatment, while helping physicians better understand a patient’s benefit-risk profile.” In an independent statistical analysis led by Timothy Spelman and Helmut Butzkueven, M.D. at the University of Melbourne, with contribution by Fabio Pellegrini and Annie Zhang, TYSABRI demonstrated a significantly lower rate of first relapse compared to interferon beta and glatiramer acetate.
News For ELN;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
11:08 EDTBIIBBiogen to add PML info on Tecfidera label after patient dies
Subscribe for More Information
11:04 EDTBIIBFDA says Biogen adding PML information on Tecfidera label
November 24, 2014
07:59 EDTBIIBBiogen resumed with an Outperform at Leerink
Subscribe for More Information
November 19, 2014
07:52 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
07:21 EDTBIIBBiogen price target lowered to $400 from $425 at Credit Suisse
Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.
November 13, 2014
10:42 EDTBIIBSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
November 12, 2014
08:13 EDTBIIBBoston Biotech to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use